Literature DB >> 26254416

The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma.

Veronica Villani1, Carmine M Carapella2, Agostino Chiaravalloti3, Irene Terrenato4, Francesca Piludu5, Antonello Vidiri5, Orazio Schillaci6, Roberto Floris3, Simona Marzi7, Alessandra Fabi8, Andrea Pace9.   

Abstract

AIM: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[(18)F]-fluoro-L-phenylalanine ([(18)F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. PATIENTS AND METHODS: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [(18)F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease.
RESULTS: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression.
CONCLUSION: These findings suggest that the PET [(18)F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Low-grade glioma; PET 18F-FDOPA; prognostic factors; progressive disease

Mesh:

Substances:

Year:  2015        PMID: 26254416

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.

Authors:  Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

Review 2.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

3.  Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

Authors:  A Verger; D Taieb; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

4.  A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Authors:  Sibel Isal; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Sophie Planel; Mohammad B Chawki; Gilles Karcher; Pierre-Yves Marie; Luc Taillandier; Antoine Verger
Journal:  Br J Radiol       Date:  2018-01-12       Impact factor: 3.039

5.  IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Authors:  A Verger; Ph Metellus; Q Sala; C Colin; E Bialecki; D Taieb; O Chinot; D Figarella-Branger; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-14       Impact factor: 9.236

6.  18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Authors:  Chirag B Patel; Elisa Fazzari; Ararat Chakhoyan; Jingwen Yao; Catalina Raymond; Huytram Nguyen; Jasmine Manoukian; Nhung Nguyen; Whitney Pope; Timothy F Cloughesy; Phioanh L Nghiemphu; Johannes Czernin; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-04-20       Impact factor: 4.130

7.  Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.

Authors:  Maria C Rossi Espagnet; Andrea Romano; Valeria Mancuso; Francesco Cicone; Antonio Napolitano; Claudia Scaringi; Giuseppe Minniti; Alessandro Bozzao
Journal:  Br J Radiol       Date:  2016-08-09       Impact factor: 3.039

Review 8.  Clinical application of 18F-DOPA PET/TC in pediatric patients.

Authors:  Gabriele Masselli; Emanuele Casciani; Cristina De Angelis; Saadi Sollaku; Gianfranco Gualdi
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

9.  Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.

Authors:  Nina Poetsch; Adelheid Woehrer; Johanna Gesperger; Julia Furtner; Alexander R Haug; Dorothee Wilhelm; Georg Widhalm; Georgios Karanikas; Michael Weber; Ivo Rausch; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Matthias Preusser; Tatjana Traub-Weidinger
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

10.  Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas.

Authors:  Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Jingwen Yao; Talia C Oughourlian; Issei Ueda; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Shadfar Bahri; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2021-03-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.